Dr. Drew Pinsky's personal battle with prostate cancer inspires him to join forces with PCF
The Prostate Cancer Foundation (PCF) announced that Drew Pinsky, MD has been elected to the Board of Directors.
“Drew has valuable experience in internal and addiction medicine,” said Jonathan W. Simons, MD, president and CEO of PCF. “As one of approximately 16 million prostate cancer survivors worldwide, Drew brings personal perspectives and counsel on a broad scope of critical issues important to our mission to improve and save lives from prostate cancer. He also brings the view of a family doctor to those in all walks of life.
"After my personal battle with prostate cancer, I decided to join forces with PCF to help spread the word about its researchers' latest life-saving breakthroughs," comments Dr. Drew Pinsky. "PCF's commitment to curing prostate cancer has accelerated discoveries that will ultimately benefit all cancers. I'm honored that I have been asked to serve on the Board of such a prestigious foundation."
Pinsky is a practicing physician and a member of the staff of Huntington Memorial Hospital. He is also assistant clinical professor of psychiatry at the Keck USC School of Medicine.
Pinsky is a radio and television personality. He starred in the hit reality series Celebrity Rehab with Dr. Drew, which chronicled the struggle for sobriety and the cycle of addictive disorders of a group of celebrities. In December 2010, Pinsky joined HLN as the host of his own nightly show Dr. Drew On Call where he continues to attract audiences and explores what makes people do what they do. Pinsky is also the host of the nationally syndicated radio show Loveline where he has been taking calls from listeners for over 25 years.
In addition, Pinsky hosts the Dr. Drew Podcast, which is currently the #1 health podcast on iTunes. Pinsky also hosts The Adam and Dr. Drew Podcast, along with his former Loveline co-host, Adam Corolla.
Pinsky is an accomplished author. He wrote the New York Times bestseller The Mirror Effect: How Celebrity Narcissism is Seducing America (Harper-Collins) and Cracked: Putting Broken Lives together Again (Harper-Collins). Pinsky co-authored the first academic study on celebrities and narcissism. The study was published in the Journal of Research in Personality (Elsevier).
Pinsky received his undergraduate degree from Amherst College and his M.D. from the University of California, School of Medicine. Pinsky remained at USC for his residency. Pinsky then became chief resident at Huntington Hospital in Pasadena. He is a diplomat of the American Board of Addiction Medicine and the American Board of Internal Medicine. He has been appointed to the Alpha Omega Alpha Honor Medical Society and is a Fellow with the American College of Physicians (FACP).
Pinsky lives in Pasadena, California with his wife Susan and has triplets.
To learn more, go to: pcf.org/manhood-for-good
About the Prostate Cancer Foundation
The Prostate Cancer Foundation is the world's leading philanthropic organization funding and accelerating prostate cancer research. Founded in 1993, PCF has raised more than $595 million and provided funding to more than 2,000 research programs at nearly 200 cancer centers and universities in 18 countries and territories. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. Its efforts have helped produce a 20-fold increase in government funding for prostate cancer. More information about the PCF can be found at www.pcf.org.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.